The Drugs Controller General of India (DCGI) granted Bharat Biotech, the developer of Covaxin, permission to conduct trials of its intranasal booster doses against Covid-19 on Friday (BBV154).
The trials will take place at nine different locations across India, according to news agency ANI.
Bharat Biotech gets DCGI's nod to conduct intranasal booster dose trials
— ANI Digital (@ani_digital) January 28, 2022
Read @ANI Story | https://t.co/Cz3V8XmRkh#COVID19Vaccine #dcgi #BharatBiotech pic.twitter.com/AtIafRyuRe
The DCGI letter stated, "The Phase-3 clinical trial should be done as per protocol multi-centre study to compare immunogenicity and safety of BBV154 with Covaxin."
It would be easier to deliver an intranasal vaccine as a booster dose in mass immunisation efforts, and it would have the ability to prevent transmission.
Last month, Bharat Biotech applied to the FDA for permission to undertake phase 3 trials on the nasal vaccination. The decision comes shortly after Covaxin and Covishield, both from the Serum Institute of India, were given market clearance.
Latest Videos
